K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.29 CAD -0.19% Market Closed
Market Cap: 534.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one GUD stock under the Base Case scenario is 6.31 CAD. Compared to the current market price of 5.29 CAD, Knight Therapeutics Inc is Undervalued by 16%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GUD Intrinsic Value
6.31 CAD
Undervaluation 16%
Intrinsic Value
Price
K
Worst Case
Base Case
Best Case

Valuation Backtest
Knight Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GUD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GUD?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Knight Therapeutics Inc

Provide an overview of the primary business activities
of Knight Therapeutics Inc.

What unique competitive advantages
does Knight Therapeutics Inc hold over its rivals?

What risks and challenges
does Knight Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Knight Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Knight Therapeutics Inc.

Provide P/S
for Knight Therapeutics Inc.

Provide P/E
for Knight Therapeutics Inc.

Provide P/OCF
for Knight Therapeutics Inc.

Provide P/FCFE
for Knight Therapeutics Inc.

Provide P/B
for Knight Therapeutics Inc.

Provide EV/S
for Knight Therapeutics Inc.

Provide EV/GP
for Knight Therapeutics Inc.

Provide EV/EBITDA
for Knight Therapeutics Inc.

Provide EV/EBIT
for Knight Therapeutics Inc.

Provide EV/OCF
for Knight Therapeutics Inc.

Provide EV/FCFF
for Knight Therapeutics Inc.

Provide EV/IC
for Knight Therapeutics Inc.

Show me price targets
for Knight Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Knight Therapeutics Inc?

How accurate were the past Revenue estimates
for Knight Therapeutics Inc?

What are the Net Income projections
for Knight Therapeutics Inc?

How accurate were the past Net Income estimates
for Knight Therapeutics Inc?

What are the EPS projections
for Knight Therapeutics Inc?

How accurate were the past EPS estimates
for Knight Therapeutics Inc?

What are the EBIT projections
for Knight Therapeutics Inc?

How accurate were the past EBIT estimates
for Knight Therapeutics Inc?

Compare the revenue forecasts
for Knight Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Knight Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Knight Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Knight Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Knight Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Knight Therapeutics Inc with its peers.

Analyze the financial leverage
of Knight Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Knight Therapeutics Inc.

Provide ROE
for Knight Therapeutics Inc.

Provide ROA
for Knight Therapeutics Inc.

Provide ROIC
for Knight Therapeutics Inc.

Provide ROCE
for Knight Therapeutics Inc.

Provide Gross Margin
for Knight Therapeutics Inc.

Provide Operating Margin
for Knight Therapeutics Inc.

Provide Net Margin
for Knight Therapeutics Inc.

Provide FCF Margin
for Knight Therapeutics Inc.

Show all solvency ratios
for Knight Therapeutics Inc.

Provide D/E Ratio
for Knight Therapeutics Inc.

Provide D/A Ratio
for Knight Therapeutics Inc.

Provide Interest Coverage Ratio
for Knight Therapeutics Inc.

Provide Altman Z-Score Ratio
for Knight Therapeutics Inc.

Provide Quick Ratio
for Knight Therapeutics Inc.

Provide Current Ratio
for Knight Therapeutics Inc.

Provide Cash Ratio
for Knight Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Knight Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Knight Therapeutics Inc?

What is the current Free Cash Flow
of Knight Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Knight Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Knight Therapeutics Inc

Current Assets 397.6m
Cash & Short-Term Investments 172.3m
Receivables 103m
Other Current Assets 122.2m
Non-Current Assets 564.7m
Long-Term Investments 105.6m
PP&E 21.6m
Intangibles 364.5m
Other Non-Current Assets 73m
Current Liabilities 118.2m
Accounts Payable 86.6m
Other Current Liabilities 31.5m
Non-Current Liabilities 70.2m
Long-Term Debt 36.5m
Other Non-Current Liabilities 33.7m
Efficiency

Earnings Waterfall
Knight Therapeutics Inc

Revenue
348.6m CAD
Cost of Revenue
-180.4m CAD
Gross Profit
168.3m CAD
Operating Expenses
-167m CAD
Operating Income
1.3m CAD
Other Expenses
-32m CAD
Net Income
-30.7m CAD

Free Cash Flow Analysis
Knight Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GUD Profitability Score
Profitability Due Diligence

Knight Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
ROIC is Increasing
38/100
Profitability
Score

Knight Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

GUD Solvency Score
Solvency Due Diligence

Knight Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Negative Net Debt
Low D/E
Short-Term Solvency
64/100
Solvency
Score

Knight Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GUD Price Targets Summary
Knight Therapeutics Inc

Wall Street analysts forecast GUD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GUD is 6.9 CAD with a low forecast of 6.16 CAD and a high forecast of 7.88 CAD.

Lowest
Price Target
6.16 CAD
16% Upside
Average
Price Target
6.9 CAD
30% Upside
Highest
Price Target
7.88 CAD
49% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GUD?

Click here to dive deeper.

Dividends

Knight Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GUD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Knight Therapeutics Inc

Country

Canada

Industry

Pharmaceuticals

Market Cap

534.2m CAD

Dividend Yield

0%

Description

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

Contact

QUEBEC
MONTREAL
3400 De Maisonneuve Blvd W
+15144844483.0
www.gud-knight.com

IPO

2014-02-28

Employees

660

Officers

Executive Chairman
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.
President, CEO & Director
Ms. Samira Sakhia BCom, CA, CPA, MBA
Chief Financial Officer
Mr. Arvind Utchanah
Chief Business Officer
Ms. Amal Khouri B.Sc., M.B.A.
Vice President of Business Development
Mr. Stephani Saverio
Vice-President of Manufacturing & Operations
Mr. Leopoldo Bosano
Show More
Global Director of Marketing
Mr. Henrique Dias
Global Vice President of Human Resources
Ms. Susan Caroline Emblem
Global Vice President of Commercial
Mr. Jeff Martens
Global Vice President of Medical & Clinical
Ms. Melanie Groleau
Show Less

See Also

Discover More
What is the Intrinsic Value of one GUD stock?

The intrinsic value of one GUD stock under the Base Case scenario is 6.31 CAD.

Is GUD stock undervalued or overvalued?

Compared to the current market price of 5.29 CAD, Knight Therapeutics Inc is Undervalued by 16%.

Back to Top